Maria De Angioletti
Florence, 50019, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 14 publications
ETV4 and ETV1-mediated downregulation of the secretory leukocyte protease inhibitor contributes to the indolent phenotype of early-stage prostate cancer.
Journal: Biochimica et biophysica acta. Molecular basis of disease
Published: February 13, 2025
SNP of Aromatase Predict Long-term Survival and Aromatase Inhibitor Toxicity in Patients with Early Breast Cancer: A Biomarker Analysis of the GIM4 and GIM5 Trials.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: May 24, 2023
The long-acting anti-C5 ravulizumab results in C3 binding to PNH red cells similar to its parental molecule eculizumab.
Journal: British journal of haematology
Published: October 31, 2022
Identification and characterization of novel ETV4 splice variants in prostate cancer.
Journal: Scientific reports
Published: September 26, 2022
ETV4 promotes late development of prostatic intraepithelial neoplasia and cell proliferation through direct and p53-mediated downregulation of p21.
Journal: Journal of hematology & oncology
Published: June 04, 2020
New NO- and H2S-releasing doxorubicins as targeted therapy against chemoresistance in castration-resistant prostate cancer: in vitro and in vivo evaluations.
Journal: Investigational new drugs
Published: January 09, 2018
Eculizumab treatment: stochastic occurrence of C3 binding to individual PNH erythrocytes.
Journal: Journal of hematology & oncology
Published: April 10, 2017
Polymorphism of the complement receptor 1 gene correlates with the hematologic response to eculizumab in patients with paroxysmal nocturnal hemoglobinuria.
Journal: Haematologica
Published: September 17, 2013
Last Updated: 09/26/2026